Bookman Michael 4

What Happened
Michael Bookman, Chief Legal Officer and Secretary of Immuneering Corp (IMRX), was granted a derivative award on 2026-02-03 covering 176,000 shares. The Form 4 reports the acquisition price as $0 because this is an option/derivative grant rather than an open-market purchase or sale. No shares were sold or exercised in this filing.

Key Details

• Transaction date: 2026-02-03; Form 4 filed 2026-02-05 (timely within the Section 16 window).
• Reported transaction: Code A — grant/award of a derivative security for 176,000 shares; reported acquisition value $0 on the Form 4.
• Vesting: The option vests in equal monthly installments over four years beginning Feb 1, 2026, and is fully vested Jan 1, 2030 (per footnote).
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or exercise reported in this filing.

Context: This filing documents a compensation-related option grant rather than a purchase or sale. Such awards are common for executive compensation and vest over time; they do not represent an immediate cash investment or divestiture by the insider.